Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Duchenne Development: Six-Minute Walk Losing Favor?

Executive Summary

Sarepta relied on the endpoint to get accelerated approval for eteplirsen, but the interim CEO says trials for follow-on products could use walk-run tests or other measures instead.

Advertisement

Related Content

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Sarepta, FDA And The Dangers Of Strong Early Results
FDA Can’t Find Efficacy For BioMarin’s Drisapersen
Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register